Innate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track Designation
08 Junio 2023 - 9:53AM
Noticias Dow Jones
By Chris Wack
Innate Pharma shares were up 8% to $3.25 after Sanofi said that
the U.S. Food and Drug Administration has granted Fast Track
Designation for SAR'579/IPH6101 for the treatment of hematological
malignancies.
Fast Track Designation is an FDA process designed to facilitate
the development, and expedite the review of, medicines to treat
serious conditions and fill unmet medical need.
SAR'579 is a trifunctional anti-CD123 cell engager from a joint
research collaboration between Innate Pharma and Sanofi, now under
development by partner Sanofi.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 08, 2023 10:38 ET (14:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Innate Pharma (EU:IPH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Innate Pharma (EU:IPH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024